The Competition and Markets Authority (CMA) has ceased its efforts to disqualify senior executives from the private equity firm Cinven from serving as directors of British companies. These executives were under scrutiny regarding allegations of drug price gouging. The development, noted on October 30, 2025, indicates that the executives had intended to contest any attempt by the competition watchdog to ban them from boards in the UK.
This decision comes after an earlier investigation related to excessive pricing in the pharmaceutical sector. While the specific drug in question and the scale of the alleged gouging are not detailed in the provided information, the focus was on the executives' involvement and potential repercussions for their corporate roles.
The CMA's action would have been a significant move, given its power to impose boardroom bans on individuals found to have breached competition law. The dropping of this pursuit means that these Cinven executives will no longer face the threat of disqualification from directorships in the UK, at least concerning this particular case.
